The Mike Slive Foundation has awarded a grant to Qianben Wang, PhD, to develop a CRISPR/Cas13d-based therapeutic nanoparticle targeting the FOXA2 transcription factor to inhibit neuroendocrine prostate cancer metastasis. This project will test the safety and effectiveness of this new nanotherapy. If the nanoparticles are both safe and effective, a clinical trial will follow to evaluate their potential to benefit patients. The goal is to provide doctors with a way to destroy metastases and improve the lives of the most advanced prostate cancer patients.
